The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.
about
HMG-CoA reductase inhibitors and P-glycoprotein modulationHerb-drug interactions: review and assessment of report reliabilityPharmacokinetic interactions of drugs with St John's wort.Tolerance and pharmacokinetics of single-dose intravenous hemoporfin in healthy volunteersReview on prescription compatibility of shaoyao gancao decoction and reflection on pharmacokinetic compatibility mechanism of traditional chinese medicine prescription based on in vivo drug interaction of main efficacious components.A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate.Herbal modulation of P-glycoprotein.Safety and efficacy of statins in Asians.New paradigms in the recognition and acute treatment of migraine.Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.A role for P-glycoprotein in environmental toxicology.Safety profile of the triptans.Triptans and CNS side-effects: pharmacokinetic and metabolic mechanisms.MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males.Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.How the Probability and Potential Clinical Significance of Pharmacokinetically Mediated Drug-Drug Interactions Are Assessed in Drug Development: Desvenlafaxine as an Example.Zolmitriptan (Zomig).Fluvastatin in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.Functional evolution of the pregnane X receptor.Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds.Caco-2 cell permeability assays to measure drug absorption.Oncologic complications of human immunodeficiency virus infection: changing epidemiology, treatments, and special considerations in the era of highly active antiretroviral therapy.Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.The emerging importance of transporter proteins in the psychopharmacological treatment of the pregnant patient.Interactions of grapefruit juice and cardiovascular medications: A potential risk of toxicity.The pharmacological management of migraine, part 1: overview and abortive therapy.Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?Tissue-specific alterations in expression and function of P-glycoprotein in streptozotocin-induced diabetic rats.The right compound in the right assay at the right time: an integrated discovery DMPK strategy.Anthracyclines as effective anticancer drugs.Clinically significant drug interactions with atypical antipsychotics.In vitro and in vivo evaluation of the effects of duloxetine on P-gp function.The Influence of Multiple-Dose Vorapaxar, an Oral PAR-1 Receptor Antagonist, on the Single-Dose Pharmacokinetics and Pharmacodynamics of Digoxin.Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model.Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.Bortezomib, carfilzomib and ixazomib do not mediate relevant transporter-based drug-drug interactionsAntiviral drugs with extra-cellular sites of action.Possible interaction between intravenous azithromycin and oral cyclosporine.Compound cardiac toxicity of oral erythromycin and verapamil.
P2860
Q28360140-8C00939C-C4E7-429A-987A-C613A9A344D1Q28365912-AB312DD5-1E1F-4734-A9A4-82F8E4DE0DFDQ33204911-85B04F39-B7D0-4F8E-BA49-4CDA6DD8FFA1Q33566788-5CE95B72-7610-46B5-90EF-51A5A8ED4FBFQ34043556-8B609969-9622-4E00-B185-3A9BC572E78EQ34180397-0CA3567C-E2D5-44BB-9640-D8C27B0EB533Q34312035-66FDFB8A-0606-44F0-B74F-58816AD8654AQ34574500-6B572671-F60B-4337-83E6-B4390CB9FA2EQ34634345-0A3246D2-66AC-44FC-B6B9-2F036FAEB055Q35000765-B532CF86-6DE3-495E-90DD-7E3E1C3644E8Q35127178-75AAADC1-6745-491F-8449-7450A0E6FB7DQ35194407-5310CD04-13E2-4962-B9E6-42B33E620BA6Q35779019-92C7DF39-2112-4EC9-8AF9-5333C4B8033DQ35804210-BC4F618B-6CD9-426A-A95E-9B5487EE78FCQ35876954-540F527B-DF05-4D69-BAE2-330140F1C7DAQ36028281-E448F87C-C463-4F5A-8FEB-509B41F2C5A9Q36107241-480B2D4B-D4EC-40F4-AD5C-CAE9CD09F0A4Q36163801-8AB4A0E3-6199-437B-8655-CF230C6C3D07Q36440155-7F46766E-9D32-46FB-8EAF-5A6B0BC13899Q36440873-0FA1A159-AF85-43B9-BC6B-751AF1E27E8FQ36572562-C7416A3E-A0FF-4103-9440-8AA092B96FD5Q36693871-71B9E0FA-7C6E-4DA8-B6E7-5FB9060F30D6Q36701911-3A2C8632-47DA-4134-ABD1-599C9093778FQ37024001-9C9A3959-8DE3-41AE-BFE9-5A62BEB2FDCFQ37276411-54D18457-7792-4BAD-B38E-6C66CE156668Q37340160-C943FA3C-77E6-434F-AD4E-CC4AD149F87BQ37663392-3004D8B4-1331-4FEA-BAA3-A9337950B6F6Q37729499-EEDA7CC6-3FF6-4C3E-8AEC-4CE892D99290Q38018653-76D26EA9-4492-484F-ACB2-A3DEB6C73162Q38090650-6A6BDDE7-EF0A-4A59-A425-FE86754EF2AFQ38156416-C2B4CF07-9D91-4E2F-B19A-B9D41DFC3A4FQ39594120-16647F00-D0D4-41D3-B273-755692B888CDQ39816501-AC2E4DB7-B0CC-4EE2-8706-642158DC94FFQ39941183-1E88DE3E-C098-4891-94C7-4E2886DFAEBDQ40656918-3D39DF33-E003-4415-90F8-58D717A82143Q40780592-485DF0C7-1C71-40C9-ACAD-3B6F5B24B2DDQ41620033-938A3800-E068-4986-9409-4AB9F84CA67BQ43759388-6B731B6F-00BE-4AEB-8767-05B2FF1A1A4DQ43803090-10EF02F2-62FB-485B-9F14-4C869C199D1DQ43809494-CEB07756-CF1D-4510-AB6F-755218FAC64C
P2860
The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.
description
1999 nî lūn-bûn
@nan
1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.
@ast
The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.
@en
type
label
The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.
@ast
The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.
@en
prefLabel
The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.
@ast
The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.
@en
P2860
P1476
The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions.
@en
P2093
P2860
P304
P356
10.1177/00912709922012006
P577
1999-12-01T00:00:00Z